Advertisement: CJBS mid banner
Advertisement: Kao Data Centre mid banner
Barr Ellison Solicitors – commercial property
Advertisement: partnersand mid banner
Advertisement: HCR Hewitsons recruitment mid banner
ARM Innovation Hub
Advertisement: Cambridge Network mid banner
Advertisement: RSM mid banner
Advertisement mid banner S-Tech 1
Advertisement: Mogrify mid banner
Advertisement: Excalibur Healthcare mid banner
Mid banner advertisement: BDO
Advertisement: EBCam mid banner
Advertisement: Simpsons Creative
7 April, 2021 - 22:41 By Tony Quested

Rosetta Capital buys into Cambridge drug discovery firm’s ‘Mission’

Mission Therapeutics, the Cambridge-based drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), has appointed Jonathan Hepple to the company’s board as a non-executive director.

He joins the board following the purchase of Schroder Adveq’s entire holdings in Mission by Rosetta Capital, of which he is co-founder. The transaction was completed recently as part of the sale of a portfolio of seven assets, including holdings in Carrick Therapeutics, PsiOxus Therapeutics, Mereo BioPharma, Inivata, Immunocore and ReNeuron, as well as Mission.

Hepple brings more than 20 years’ investment experience in the life sciences industry. Since founding Rosetta Capital, a leading life sciences-focused international secondary venture firm, he has held the position of director. Alongside this role, he is also strategic advisor to Oxford Sciences Innovation.

His previous roles include founder and director of BioScience Managers and investment analyst at Rothschild Asset Management. He was also a partner at Seroba Life Sciences, where he was on the boards of portfolio companies Covagen and Opsona.

An experienced non-executive director, he has acted on the boards of numerous life sciences companies, most recently Aprea and Clanotech. 

Hepple said: “Despite the current global challenges, Mission has continued to go from strength to strength. The expansion of its senior team and repertoire of high calibre partnerships, such as its collaboration with AbbVie and expanded relationship with Pfizer, are indicative of the growth and huge potential of the company. I am delighted to be joining the Board at this pivotal time.”

Newsletter Subscription

Stay informed of the latest news and features